{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T20:07:33Z","timestamp":1770408453447,"version":"3.49.0"},"reference-count":93,"publisher":"Informa UK Limited","issue":"3","funder":[{"name":"funded"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Pharmacotherapy"],"published-print":{"date-parts":[[2023,2,11]]},"DOI":"10.1080\/14656566.2022.2161883","type":"journal-article","created":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T15:47:40Z","timestamp":1671724060000},"page":"359-375","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":3,"title":["An update on the use of pharmacotherapy for opioid-induced bowel dysfunction"],"prefix":"10.1080","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1976-6789","authenticated-orcid":false,"given":"Taraneh","family":"Mousavi","sequence":"first","affiliation":[{"name":"Faculty of Pharmacy","place":["Tehran, Iran"]},{"name":"Tehran University of Medical Sciences","place":["Tehran, Iran"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5206-6197","authenticated-orcid":false,"given":"Shekoufeh","family":"Nikfar","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy","place":["Tehran, Iran"]},{"name":"Tehran University of Medical Sciences","place":["Tehran, Iran"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0123-1209","authenticated-orcid":false,"given":"Mohammad","family":"Abdollahi","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy","place":["Tehran, Iran"]},{"name":"Tehran University of Medical Sciences","place":["Tehran, Iran"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2022,12,28]]},"reference":[{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2018.07.016"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-021-01766-y"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1177\/2050640618818305"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.15791"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-813037-7.00033-9"},{"issue":"7","key":"e_1_3_4_8_1","first-page":"e16201","article-title":"Efficacy and safety of peripherally acting \u03bc-opioid receptor antagonist (PAMORAs) for the management of patients with opioid-induced constipation: a systematic review","volume":"13","author":"Rekatsina M","year":"2021","unstructured":"Rekatsina M, Paladini A, Drewes AM Efficacy and safety of peripherally acting \u03bc-opioid receptor antagonist (PAMORAs) for the management of patients with opioid-induced constipation: a systematic review. Cureus. 2021 Jul;13(7):e16201.","journal-title":"Cureus"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12904-020-00693-z"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.sjpain.2017.01.006"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-022-02090-9"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-018-4366-z"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1080\/15360288.2020.1828529"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/pm\/pnaa152"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/164_2016_116"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.2147\/CEG.S52097"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.5056\/jnm15175"},{"issue":"11","key":"e_1_3_4_18_1","doi-asserted-by":"crossref","first-page":"e14131","DOI":"10.1111\/nmo.14131","article-title":"Tapentadol results in less deterioration of gastrointestinal function and symptoms than standard opioid therapy in healthy male volunteers","volume":"33","author":"Mark EB","year":"2021","unstructured":"Mark EB, Nedergaard RB, Hansen TM Tapentadol results in less deterioration of gastrointestinal function and symptoms than standard opioid therapy in healthy male volunteers. Neurogastroenterology Motil off J Eur Gastrointestinal Motil Soc. 2021 Nov;33(11):e14131.","journal-title":"Neurogastroenterology Motil off J Eur Gastrointestinal Motil Soc"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2354.2011.01286.x"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-019-04944-5"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/pm\/pnw240"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.3344\/kjp.2019.32.2.69"},{"key":"e_1_3_4_23_1","unstructured":"Maryland USFDANALOXONEHYDROCHLORIDE United States: u.S. Food and Drug Administration 2022 [cited 2022 August 13]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/215457s000lbl.pdf"},{"key":"e_1_3_4_24_1","unstructured":"TGA. NARCAN naloxone hydrochloride Symonston Australia Therapeutic Goods Administration; 2022 [cited 2022 August 13]. Available from: https:\/\/www.ebs.tga.gov.au\/servlet\/xmlmillr6?dbid=ebs\/PublicHTML\/pdfStore.nsf&docid=DA25D0E21B6BF597CA25871B004267AA&agid=(PrintDetailsPublic)&actionid=1"},{"key":"e_1_3_4_25_1","unstructured":"EMA. Nyxoid Amsterdam Netherlands: European Medicines Agency; 2022 [cited 2022 August 13]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/nyxoid"},{"key":"e_1_3_4_26_1","unstructured":"EMA. Oxynal Targin Amsterdam Netherlands: European Medicines Agency; 2022 [cited 2022 August 14]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/referrals\/oxynal-targin-associated-names"},{"key":"e_1_3_4_27_1","unstructured":"EMA. Rizmoic Amsterdam Netherlands: European Medicines Agency; 2022 [cited 2022 August 14]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/rizmoic"},{"key":"e_1_3_4_28_1","unstructured":"TGA. Symproic Symonston Australia: Therapeutic Goods Administration; 2017 [cited 2022 August 14]. Available from: https:\/\/www.pmda.go.jp\/files\/000222647.pdf"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/ejp.1054"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2017.07.025"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2018.1420778"},{"key":"e_1_3_4_32_1","unstructured":"USFDA. TARGINIQ ER (oxycodone hydrochloride and naloxone hydrochloride extended-release tablets) Maryland United States: U.S. Food and Drug Administration 2016 [cited 2022 August 14]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/205777s004lbl.pdf"},{"key":"e_1_3_4_33_1","unstructured":"USFDA. ENTEREG (alvimopan) Maryland United States: u.S. Food and Drug Administration 2008 [cited 2022 August 14]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2008\/021775lbl.pdf"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2010.06.012"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2018.1491549"},{"key":"e_1_3_4_36_1","unstructured":"USFDA. RELISTOR (methylnaltrexone bromide) Maryland United States: u.S. Food and Drug Administration; 2016 [cited 2022 August 13]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/208271s000lbl.pdf"},{"key":"e_1_3_4_37_1","unstructured":"TGA. RELISTOR methylnaltrexone bromide Symonston Australia: therapeutic Goods Administration; 2022 [cited 2022 August 13]. Available from: https:\/\/www.ebs.tga.gov.au\/servlet\/xmlmillr6?dbid=ebs\/PublicHTML\/pdfStore.nsf&docid=144062&agid=(PrintDetailsPublic)&actionid=1"},{"key":"e_1_3_4_38_1","unstructured":"EMA. Relistor Amsterdam Netherlands: European Medicines Agency; 2022 [cited 2022 August 13]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/relistor"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2019.09.1016"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40122-021-00237-0"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-019-05913-6"},{"key":"e_1_3_4_42_1","unstructured":"USFDA. MOVANTIK (naloxegol) Maryland United States: u.S. Food and Drug Administration; 2014 [cited 2022 Aug 13]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/204760s000lbl.pdf"},{"key":"e_1_3_4_43_1","unstructured":"EMA. Moventig Amsterdam Netherlands: European Medicines Agency; 2022 [cited 2022 August 13]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/moventig"},{"key":"e_1_3_4_44_1","unstructured":"TGA. MOVANTIK Symonston Australia: Therapeutic Goods Administration; 2016 [cited 2022 August 13]. Available from: https:\/\/www.tga.gov.au\/sites\/default\/files\/auspar-naloxegol-oxalate-160601-pi.pdf"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14051128"},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjspcare-2020-002249"},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.08.1515"},{"key":"e_1_3_4_48_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjspcare-2020-002249"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz265.066"},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-016-0454-4"},{"key":"e_1_3_4_51_1","unstructured":"USFDA. SYMPROIC (naldemedine) Maryland United States: u.S. Food and Drug Administration 2017 [cited 2022 Aug 14]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/208854s000lbl.pdf"},{"key":"e_1_3_4_52_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-019-01160-7"},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2019.04.774"},{"key":"e_1_3_4_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(17)30105-X"},{"key":"e_1_3_4_55_1","doi-asserted-by":"publisher","DOI":"10.2147\/JPR.S282738"},{"key":"e_1_3_4_56_1","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2019.1570845"},{"key":"e_1_3_4_57_1","doi-asserted-by":"publisher","DOI":"10.1177\/17562848221078638"},{"key":"e_1_3_4_58_1","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2019-000527"},{"key":"e_1_3_4_59_1","unstructured":"USFDA. Linzess (Linaclotide) Maryland United States: u.S. Food and Drug Administration 2017 [cited 2022 August 13]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/202811s013lbl.pdf"},{"key":"e_1_3_4_60_1","unstructured":"PMDA. List of Approved Products Tokyo Japan Pharmaceuticals and Medical Devices Agency; 2022 [cited 2022 August 13]. Available from: https:\/\/www.pmda.go.jp\/english\/review-services\/reviews\/approved-information\/drugs\/0002.html"},{"key":"e_1_3_4_61_1","unstructured":"TGA. CONSTELLA linaclotide 290 microgram hard capsule bottle Symonston Australia Therapeutic Goods Administration; 2019 [cited 2022 August 13]. Available from: https:\/\/www.ebs.tga.gov.au\/servlet\/xmlmillr6?dbid=ebs\/PublicHTML\/pdfStore.nsf&docid=84C1E315FD38B06CCA2587300042389F&agid=(PrintDetailsPublic)&actionid=1"},{"key":"e_1_3_4_62_1","doi-asserted-by":"crossref","unstructured":"Mousavi T Nikfar S Abdollahi M. An update on efficacy and safety considerations for the latest drugs used to treat irritable bowel syndrome. Expert opinion on drug metabolism & toxicology. 2020;16(7):583\u2013604.","DOI":"10.1080\/17425255.2020.1767067"},{"key":"e_1_3_4_63_1","doi-asserted-by":"publisher","DOI":"10.1097\/j.pain.0000000000001754"},{"key":"e_1_3_4_64_1","unstructured":"TGA. Australian Public Assessment Report for Prucalopride Symonston Australia: Therapeutic Goods Administration; 2011 [cited 2022 August 13]. Available from: https:\/\/www.tga.gov.au\/sites\/default\/files\/auspar-resotrans.pdf"},{"key":"e_1_3_4_65_1","unstructured":"USFDA. MOTEGRITY (prucalopride) Maryland United States: u.S. Food and Drug Administration 2018 [cited 2022 Aug 13]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/210166s000lbl.pdf"},{"key":"e_1_3_4_66_1","unstructured":"USFDA. AMITIZA (lubiprostone) Maryland United States: u.S. Food and Drug Administration 2018 [cited 2022 August 13]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/021908s016lbl.pdf"},{"key":"e_1_3_4_67_1","unstructured":"Japan P Amitiza Gets Label Update for Opioid-Induced Constipation: Pharma Japan; 2021 [cited 2022 August 13]. Available from: https:\/\/pj.jiho.jp\/article\/245632"},{"key":"e_1_3_4_68_1","doi-asserted-by":"publisher","DOI":"10.1093\/pm\/pnx212"},{"key":"e_1_3_4_69_1","doi-asserted-by":"publisher","DOI":"10.3164\/jcbn.19-118"},{"key":"e_1_3_4_70_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269216311404273"},{"key":"e_1_3_4_71_1","article-title":"Nausea and vomiting in people with cancer and other chronic diseases","volume":"2009","author":"Keeley PW","year":"2009","unstructured":"Keeley PW. Nausea and vomiting in people with cancer and other chronic diseases. BMJ Clin Evid. 2009 Jan 13;2009:2406.","journal-title":"BMJ Clin Evid"},{"key":"e_1_3_4_72_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2006.10.020"},{"key":"e_1_3_4_73_1","first-page":"1","article-title":"Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting: a Comparative Study From Sudan","volume":"4","author":"Osman AAM","year":"2018","unstructured":"Osman AAM, Elhassan MMA, AbdElrahim BHA Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting: a Comparative Study From Sudan. J Glob Oncol. 2018 Sep;4:1\u20139.","journal-title":"J Glob Oncol"},{"key":"e_1_3_4_74_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-001-0332-1"},{"key":"e_1_3_4_75_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(00)80024-7"},{"key":"e_1_3_4_76_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2346.1999.00547.x"},{"key":"e_1_3_4_77_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-019-04688-2"},{"key":"e_1_3_4_78_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-019-0686-6"},{"key":"e_1_3_4_79_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2020.3285"},{"key":"e_1_3_4_80_1","doi-asserted-by":"publisher","DOI":"10.1188\/20.ONF.E211-E224"},{"key":"e_1_3_4_81_1","doi-asserted-by":"publisher","DOI":"10.1188\/20.ONF.671-691"},{"key":"e_1_3_4_82_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14092112"},{"issue":"4","key":"e_1_3_4_83_1","first-page":"e14386","article-title":"Opioid-Induced Constipation in Advanced Cancer Patients","volume":"13","author":"AL N","year":"2021","unstructured":"AL N. Opioid-Induced Constipation in Advanced Cancer Patients. Cureus. 2021 Apr 9;13(4):e14386.","journal-title":"Cureus"},{"key":"e_1_3_4_84_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2018.02.038"},{"key":"e_1_3_4_85_1","first-page":"112","article-title":"Effectiveness of Various Treatment Agents for Opioid-Induced Constipation: a Meta-Analysis: 428","author":"Saleem R","year":"2017","unstructured":"Saleem R, Syed T, Nusrat S Effectiveness of Various Treatment Agents for Opioid-Induced Constipation: a Meta-Analysis: 428. Am J Gastroenterol. 2017;112:S229.","journal-title":"Am J Gastroenterol"},{"key":"e_1_3_4_86_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2018.01.021"},{"key":"e_1_3_4_87_1","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.14586"},{"key":"e_1_3_4_88_1","doi-asserted-by":"publisher","DOI":"10.1097\/AJP.0000000000000852"},{"key":"e_1_3_4_89_1","doi-asserted-by":"publisher","DOI":"10.1093\/pch\/pxz165"},{"issue":"1","key":"e_1_3_4_90_1","article-title":"Recognizing and Treating Opioid-Induced Constipation in Chronically Ill Children","volume":"45","author":"Rosenberg JB","year":"2019","unstructured":"Rosenberg JB. Recognizing and Treating Opioid-Induced Constipation in Chronically Ill Children. Pediatr Nurs. 2019;45(1):p7\u201346.","journal-title":"Pediatr Nurs"},{"key":"e_1_3_4_91_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajgsup.2014.6"},{"key":"e_1_3_4_92_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(16)30217-5"},{"key":"e_1_3_4_93_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.9.2542"},{"key":"e_1_3_4_94_1","doi-asserted-by":"publisher","DOI":"10.1177\/026921639100500408"},{"key":"e_1_3_4_95_1","doi-asserted-by":"publisher","DOI":"10.1089\/jpm.2018.0260"}],"container-title":["Expert Opinion on Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14656566.2022.2161883","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T09:11:22Z","timestamp":1770369082000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14656566.2022.2161883"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,28]]},"references-count":93,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,2,11]]}},"alternative-id":["10.1080\/14656566.2022.2161883"],"URL":"https:\/\/doi.org\/10.1080\/14656566.2022.2161883","relation":{},"ISSN":["1465-6566","1744-7666"],"issn-type":[{"value":"1465-6566","type":"print"},{"value":"1744-7666","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,28]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2022-08-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-12-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-12-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}